11 第25回がん学会一般演題一覧（第3会場）
|
|
|
- ようじろう さかわ
- 4 years ago
- Views:
Transcription
1
2 1) 2) 1) 2) KTSND KTSND KTSND
3 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR CT 6
4 62 20XX 6 CTMRI DIC methotrexatemtx /5-FU DIC score ALP performance status grade 2 90%DIC MTX/5-FU 1st line
5
6 75 Sjogren HCV IFN PEG-IFN/RBV S4 S4 Moderately differentiated hepatocellular carcinomapt1nxmx, pstage I (CART) Child-Pugh A Denver Shunt CART 1 5 CART Child A Sofosubuvir+ledipasvir C
7
8 2 3 progrp NSE CYFRA CEA /6/21/2/3/42/4/1/1 3 (26)CR/PR/SD/PD0/3/3/2PFS97.5 CYFRA/NSE PRSD CYFRA/NSE (re-biopsy)
9 Aero Stent TM Aero Stent TM nitinol Aero Stent TM mm 40mm 2 web 3mm APC web 16mm 40 mm multi-detector CT Aero Stent TM Ultraflex X
10 1) 1) 1) 2) 1)2) (31 6 )1 1 BMI ( )30 (77%)(18.5 )3 (8%)(25 )6 (15%) 28 (72%)24 (62%)24 (62%) 19 (49%) (31%)7 (58%)
11 GI-NET R0 R1 GI-NET G110 G20 NEC13 2 G1100%NEC23.1 G1NEC G1100%NEC38.1% NEC 3 NET G1 GI-NET G1 NEC
12 DCS+
13 GKRS database GKRS3000 database (IRB #1981) % % % NSCLC 1660[55.3%] SCLC 283[9.4%] % %1214.0%2448.1% Modified-RPA class 1+2a 2b 2c % % % JMP12.0 MacintoshKaplan-MeireCox proportional hazard model % % lost to follow-up % %GKRS7.895% CI; GKRS % 15.9% 8.9% 6.1% 4.8%Modified-RPA class 1+2a 2b 2c % CI; % CI; HR [2b vs 1+2a]; % CI; p< % CI; HR [2c+3 vs 2b]; % CI; p< HR; % CI; p< HR; % CI; p=0.0006HR; % CI; p< cchr; % CI; p< KPS 80%HR; % CI; p<0.0001hr; % CI; p< HR; % CI; p<0.0001hr; % CI; p<0.0001GKRSsalvage treatment GKRS %1053.5%421.4% 852.8%RTOG neuro-toxicity grade % %GKRS % GKRS %76.5%68.2%63.9% 59.8% GKRS % 80.2% 72.9% 68.8%66.2% GKRSbig data Modified-RPA class 1+2a 2b
14
15
16 1), 1), 1), 1), 2) 1) 2) CT 17cm stromal tumor of uncertain malignant potential (STUMP) GEM+DTX SD malignant potential TAE Solitary fibrous tumor with atypical features 12 CT Solitary fibrous tumor
17 1 1) 1) 1) 1) 1) 2) 1)2) CIS 2011 HPV CIN CIS 80 RALS HSIL CIS UCF SCC1.0ng/ml MRI CT 80 t brachytherapy RALS 5 29Gy 1 2 CIS brachytherapy option
18 HPV HNSCC 15 20Human papilloma virus (HPV)HNSCC HPV HNSCC HPV HPV HNSCC HPV 90HPV-16 HNSCC HPV HPV HNSCC HPV HNSCC p16 HPV HNSCC p16 HPV HPV HNSCC 40 HNSCC HNSCC HPV 3 2 HPV p16 1/71/64/60/70/20/1 HPV PCR in situ hybridization HPV p16 PCR p16 HPV HPV p16 HPV p16 HPV HNSCC p16 HPV HPV HNSCC
19 1 1 53,3 20mm MRI T2 Gd 10mm Alcian-Blue pan-ck(+) p63(+) p40(+) S-100(-)calponin(-)a-SMA(-) CTMRI(Ga )
20
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
広報さがみはら第1242号
LINE UP 3 1 5 6 1 NO.1242 S A G A M I H A R A 1 1 1 16 16 1 6 1 6 1 6 1 1 1 1 1 11 1 1 1 1 1 1 6 1 6 1 1 1 1 1 1 1 1 11 1 1 16 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 16 1 16 1 6 1 1 1 1 1 1
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2)
General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2) (3) (4) (Standard Precautions ) (5) ( ) (6) (7) ( ) ( ) QOL(Quality of Life) ( ) (8) 1 2 (1) (2) (3) 4 24 (4) 3 ABC3 (common
「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について（第1報）」について
2012 3 28 2011 3 1 1 2012 3 2012 3 28 2012 3 28 2012 3 28 2012 3 28 1. 1 3 11 1 2 3 15 17 3 4 5 1 2012 3 28 5 10 6 3 18 7 5 8 3 23 9 2 2012 3 28 2011 3 23 23 10 3 2012 3 28 4 2012 3 28 5 2012 3 28 3 24
評価結果報告書の概要版（平成20年度）
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
41-6_50回中国地方会Pr6N__HP掲載用.indd
2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.
瀬田唐橋景観検討について
3 3 12,174 /12hr 1,110 /12hr 3,066 /12hr 172.0m 51.75m 23.5+5@25.0+23.5m 3@17.25m 14.0m 15.0m 5 6 2009 12 3 2010 2 25 6/22 8/24 10/18 11/16 1/13 1797 16 15 15 13 6 (S49) 54 7 23-2 24 54 50
124
[ ] [ ] 18 123 124 ( ) 125 126 127 128 5,683,062 2,306,419 18.2 14.0 12 5389 87 13 257 88 12 22 27 56.7 41.6 1 1.7 15 129 55 38.8 13.3 15 2004 15 1 3 84.8 29.3 1 23.9 38.0 10 10 35 35 15 5 56.5.31 55.4.1
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
被曝二世健康影響調査
19 3 1 1. 3 2. 4 4 4 6 7 8 8 3. 10 10 10 11 12 4. 14 14 15 15 15 15 16 17 17 18 18 19 19 5. 20 6. 21 22 2000 7 5 4 6 4 77,000 5mGy 5mGy 24,673 57.3 84.5% 11,951 BMI 1 - 1Gy 0.91 1Gy 0.98-48.6 48.4 19 10
8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
取扱説明書 [F-08D]
![取扱説明書 [F-08D]](/thumbs/48/23832237.jpg "取扱説明書 [F-08D]")
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
2002 715 02-13M 1. 200110 024 2. 3. 4. 100 60 5. 6. 2002715 1 1 1 4 9 9 12 12 13 14 14 15 15 17 17 18 22 22 23 25 25 25 29 200110 024 3 1 1965 500 800 3,000 2,000 1 1 60 2.84 1.173 1 2002 71 1,726 1,085
![橡0420報告書最終版.ppt[読み取り専用]](/thumbs/42/22906925.jpg "橡0420報告書最終版.ppt[読み取り専用]")
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
TM Reverse Shoulder手術手技書
Zimmer Biomet Trabecular Metal Reverse Shoulder System Surgical Technique 1 Trabecular Metal Reverse Shoulder 22500BZX00475000 Vivacit-E 22700BZX00233000 2 Trabecular Metal Reverse Shoulder TM / / 3 3
56cm 1 15 1960 2 8 2 2 1 2008 1992 2 1992 2 3562mm 3773mm 2 1980 1991 2008 2007 2003 5 2 3 2003 2005 2008 2010 2005 2008 2012 2010 2012 4 7 4 5 2 1975 1994 8 2008 NPO 2 2010 3 2013 2016 3 2008 2009 14
2
2 485 1300 1 6 17 18 3 18 18 3 17 () 6 1 2 3 4 1 18 11 27 10001200 705 2 18 12 27 10001230 705 3 19 2 5 10001140 302 5 () 6 280 2 7 ACCESS WEB 8 9 10 11 12 13 14 3 A B C D E 1 Data 13 12 Data 15 9 18 2
紀要No.9_006王_CS.indd
1 2 3 4 5 87 9 2009 1937.1 6 1937.1 2 1937.3 1937.9 73 1941.6 77 1941.10 27 1943.9 1943.10 1944.12 1946.12 1947.1 5 1948.4 L 1949.9 10 1950.10 1953.1 1953.12 1956.5.16 1956.6 1966.9 30 1966.10 1967.4 1967.9
* 1 6 ( ) 20 GOT GPT ( ) 59 3 CT F D T3 *
-259 3101 * 1 6 () 20 GOTGPT 3 155169 2 5 () 59 3 CT 129 59 F D T3 * -- 428 - -259 3101 * 3 5 4 6 () 159 NOS () 158 159 R 4U T3 500ml 2ml 2g 100ml 25mg PL 162 152 152 37 1630 92mg/dl PL 3g/ 3 300mg/ 3
untitled
1 211022 2 11150 211022384 3 1000 23% 77% 10% 10% 5% 20% 15% 40% 5% 3% 8% 16% 15% 42% 5% 6% 4 =1000 = 66 5 =1000 = 59 6 52%(42% 1000 7 56% 41% 40% 97% 3% 11%, 2% 3%, 41 7% 49% 30%, 18%, 40%, 83% =1000
分布
(normal distribution) 30 2 Skewed graph 1 2 (variance) s 2 = 1/(n-1) (xi x) 2 x = mean, s = variance (variance) (standard deviation) SD = SQR (var) or 8 8 0.3 0.2 0.1 0.0 0 1 2 3 4 5 6 7 8 8 0 1 8 (probability
ヴェトナムの旅から
3 4 OB OB (2000 ) 60% 1 / 12 13 ( ) ( ) 18 111 1000 1979 2 / 12 1000 99% ( ) ( ) ( ) ( ) ( ) 3 / 12 (2009 ) 3143m 1957m 1200m A1 ( ) 4 / 12 1953 100 (1994 ) (1942 ) 1801 ( ) 1862 1882 5 / 12 1945 ( ) 80
JA2008
A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5
Gifu University Hospital Cancer Center 1 2 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center 3 4 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
<967B92AC B82DC82BF82C382AD82E88C7689E68F912E706466>
16m80m 16 4 1100 17 1 1 1 2 2 4 2 3 3 2 3 2 1 5 1 1 18 1/100 18 1 2 3 2~4 1 1 1 2 26 () 27 5 28 300 29 () 30 31 32 20229 5/30 - (83-2041) 68 2 2 1 7 1 1 4 7 7 2 1 1 2 4 1 2 181222 1 // 2 // 3 // 4 /
医療レーザー脱毛の威力と限界
.... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons
54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018
.k....-._.C.W.F.X.g01-01
20042005 Guidelines for the Clinical Application of Bypass Grafts and the Surgical Techniques (JCS 2006) 2006 11 1 2 2.1 2.1.1 CCAB 2.1.2 2.1.3 2.1.4 2.1.5 2.1.6 2.1.7 2.2 2.2.1 MIDCAB 2.2.2 2.3 CCAB OPCAB
01
2 0 0 7 0 3 2 2 i n d e x 0 7. 0 2. 0 3. 0 4. 0 8. 0 9. 1 0. 1 1. 0 5. 1 2. 1 3. 1 4. 1 5. 1 6. 1 7. 1 8. 1 9. 2 0. 2 1. 2 3. 2 4. 2 5. 2 6. O k h o t s k H a m a n a s u B e e f 0 2 http://clione-beef.n43.jp
北辰同窓会36号-02.21修正
36 FEB, 2011 20112 36 1 GDPOECD 1.5 0.1910 1 2 4 29 Web 40 3,500 22 9 1 22 4 3,279 6 6 6 6 22 7 28 208 1971 9 1976 3 1976 4 1977 11 1983 7 1989 5 Russell Ross 1990 5 1994 7 2002 4 2004 8 1122 9 125 8 313
1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm
1 1 36 223 42 14 92 4 3 2 1 4 3 4 3429 13536 5 6 7 8 9 2.4m/ (M) (M) (M) (M) (M) 6.67.3 6.57.2 6.97.6 7.27.8 8.4 5 6 5 6 5 5 74 1,239 0 30 21 ( ) 1,639 3,898 0 1,084 887 2 5 0 2 2 4 22 1 3 1 ( :) 426 1500
1 C 2 C 3 C 4 C 1 C 2 C 3 C
1 e N >. C 40 41 2 >. C 3 >.. C 26 >.. C .mm 4 C 106 e A 107 1 C 2 C 3 C 4 C 1 C 2 C 3 C 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124
(1519) () 1 ( ) () 1 ( ) - 1 - - 2 - (1531) (25) 5 25,000 (25) 5 30,000 25,000 174 3 323 174 3 323 (1532) () 2 () 2-3 - - 4 - (1533) () 1 (2267)204 () (1)(2) () 1 (2267)204 () (1)(2) (3) (3) 840,000 680,000
平成２４年財政投融資計画ＰＤＦ出後８／０１６‐０３０
24 23 28,707,866 2,317,737 26,390,129 29,289,794 2,899,665 24 23 19,084,525 21,036,598 1952,073 24 23 8,603,613 8,393,427 967,631 925,404 202,440 179,834 217,469 219,963 66,716 64,877 3,160,423 2,951,165
1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/
第18回海岸シンポジウム報告書
2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m
液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D
1 2 3 4 5 6 7 1 2 3 4 5 6 7 2 2 2 1 1 2 9 10 11 12 13 14 15 16 17 1 8 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 9 11 12 13 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 11 12
000-.\..
1 1 1 2 3 4 5 6 7 8 9 e e 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 10mm 150mm 60mm 25mm 40mm 30mm 25 26 27 1 28 29 30 31 32 e e e e e e 33 e 34 35 35 e e e e 36 37 38 38 e e 39 e 1 40 e 41 e 42 43
[mm] [mm] [mm] 70 60 50 40 30 20 10 1H 0 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 60 50 40 30 20 10 0 18 19 20 21 22 23 24 1 2 3 4
ÿþ
YV-18 YV-19 YV-20 HALS Surgrx Enseal System 5 29 16:10 17:10 1-1 YP-1 YP-2 YP-3 YP-4 YP-5 YP-6 1 20 TS1 2 5 29 16:10 17:10 1-2 YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN 1 4 3 2 Gemcitabine 5 29 16:10 17:10
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
AD 2004/8/22 1. 30 90 mmhg 2. 3 100 refilling COPD etc. etc. PCPS IVR Helical CT DSA IVR DVT US/CT Scintigaraphy Ventilation / Perfusion VP scans High probability R DSA Gold standard MSCT
- 9 91, (2006)
Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM
17 17 17 17 11 21 28 1 24 12 36 2,000 2 22 11 3.67 3.38 22 2.97 21 10 1.7 1.12 22 10 13 2.75 11 10 15 24 10 12 14 3 17 17 2006 4 17 10 24 12 17 5 15 17 17 11 40 6 17 40 17 11 7 24 17 24 17 8 40 17 17 9
